; however, it also increases bleeding risk, and its net effect on mortality is unclear, with conflicting findings from 2 recent network meta-analyses. 6, 7 In 1 network meta-analysis, Shah et al 6 estimate that in addition to aspirin, clopidogrel reduces all-cause
I n the first part (citation to be added) of a 2-part series of articles, we reviewed the epidemiology of cardiovascular disease (CVD) and its risk factors. In this second part, we summarize the proven, widely applicable and effective strategies for the prevention and treatment of CVD. In high-income countries (HIC), approaches to the prevention and treatment of CVD have halved CVD death rates during the past 20 to 30 years. It is estimated that both modifying risk factors and implementation of therapeutic strategies are responsible for this reduction in deaths, with their relative contributions varying in different countries. In countries like Finland and the United Kingdom, primary prevention and especially reduction in tobacco use is responsible for much of the reduction in premature CVD, but in countries including the western countries participating in the MONICA study (Multinational Monitoring of Trends and Determinants in Cardiovascular Disease), 1 the benefits were closely related to improved secondary prevention and use of treatments. In this article, we categorize the preventive and therapeutic approaches as high priority (if there is substantial evidence to indicate their efficacy in reducing morbidity and mortality, they are widely applicable) or desirable (if there is supportive evidence that is less compelling than for high-priority strategies, they are less widely applicable). Globally, the challenge is to deliver these high priority or desirable approaches in diverse social and economic settings among heterogeneous populations, so we will also address the role of healthcare systems in reducing the global burden of CVD in this review.
Acute CVD Care Acute Coronary Syndromes
Aspirin blocks platelet aggregation by inhibiting thromboxane A2. If administered within 24 hours of the onset of an acute coronary syndrome (ACS), it reduces mortality, reinfarction, and stroke. Given its low cost and ease of administration, it is widely accepted as an essential treatment. Aspirin is available in most of the world although 1 study found it unavailable in 20% to 30% of rural communities in middle (MIC) and low (LIC)-income countries (collectively, LMIC). 2 Aspirin's low cost (≤1% of the average households' capacity-to-pay 2 ) combined with its clear benefits in ACS make it a high-priority therapy. Clopidogrel inhibits platelet aggregation by antagonizing the platelet P2Y12 receptor. When combined with aspirin in patients with ACS, clopidogrel further reduces the risk of the composite outcome of CVD death, recurrent ACS, or stroke [3] [4] [5] included both those with ACS or prior myocardial infarction. Thus, the difference in the acuity of coronary disease may have differed between these 2 meta-analyses and may account, in part, for their contrasting findings. In HIC, the use of clopidogrel before percutaneous coronary intervention (PCI) is cost effective, with an estimated cost per life-year-gained of USD $3000-4000, 8 well below conventional willingness-to-pay thresholds in these settings. There are scant data on clopidogrel's cost effectiveness in lower-income settings; however, its cost may have fallen substantially as it has been generic since 2012. In its 2015 iteration, the World Health Organization Essential Medicines list included clopidogrel. 9 We consider clopidogrel high-priority in HIC and MIC, with further evaluation needed in LIC. Newer P2Y12 antiplatelet agents (prasugrel or ticagrelor) are more effective in reducing recurrent ischemic events compared with clopidogrel, but this benefit is offset, to some extent, by increased bleeding 10 and higher costs. Therefore, they are not regarded as high-priority medicines but rather desirable for individuals at high risk of recurrent ACS, who are not at high risk of bleeding, especially in high-income settings; they are unaffordable for most individuals in LMIC at current prices.
Thrombolytic therapy administered within 12 hours of symptom onset for ST-elevation ACS prevents 20 to 30 deaths per 1000 recipients. 11 Compared with thrombolysis, primary PCI further reduces mortality. One meta-analysis of randomized trials comparing primary PCI with thrombolysis suggested a reduction in short-term (≤6 week) mortality, with odds ratio (credible interval) 0.66 (0.51-0.82), and in long-term (≥1 year) mortality, with odds ratio (credible interval) 0.76 (0.58-0.95). 12 The success of primary PCI depends on operator experience, hospital case volumes, and the rapidity with which PCI can be performed. Primary PCI programs should be planned on a population basis, taking account of population distribution and transportation facilities. The availability of PCI in LMIC is limited because there are substantial costs in establishing and maintaining the necessary facilities and staff, so it is affordable mostly for insured individuals. In a prospective registry of 20 468 patients with ACS from 50 cities in India, fewer poorer patients (9%) than wealthy patients (41%) underwent coronary angiography, despite a higher proportion of individuals with ST-segment elevation among the poor (71%) compared with the rich (47%). 13 A more recent registry from Kerala, India, found that PCI rates appeared to have increased, however (12% versus 7.5%).
14 At a recent conference of sub-Saharan countries, it was reported that there were only 5 cardiac catheterization laboratories in total in the 10 participating countries, so coronary angiography and PCI were not available for most individuals. 15 Even in HIC with dispersed populations, significant numbers may live far from any suitably equipped facility. 16 Although reperfusion for ST-elevation ACS is a high-priority therapy, time-to-reperfusion is the most important determinant of its effectiveness. In HIC, health systems address time-to-reperfusion through planning of infrastructure, including distribution of facilities offering 24-hour reperfusion supported by rapid transport services, coupled with campaigns to raise awareness among health professionals and the public. However, this depends on the existence of a good road system and a network of health facilities, both of which are missing in many LIC. In regions, such as sub-Saharan Africa, access to appropriate facilities is a major barrier to implementation of reperfusion strategies, and further research is needed to determine whether pre-hospital thrombolysis might represent a useful means of reducing morbidity and mortality from ST-elevation ACS in these settings. 15 Most evaluations of the cost effectiveness of primary PCI come from HIC. These analyses suggest that the higher upfront cost of primary PCI is offset by lower rates of death, reinfarction, and stroke (especially from intracerebral bleeds, which are increased with thrombolytic therapy) and shorter hospital stay. This results in overall cost neutrality compared with thrombolysis. 17 Formal cost-effectiveness analyses are required to aid prioritization in LMIC.
When administered early after ACS, β-blockers reduce the risk of death (pooled relative risk [RR], 0.92; 95% CI: 0.86-1.00) or reinfarction (pooled RR, 0.73; 95% CI: 0.59-0.91). 18 This benefit may be offset by an excess of cardiogenic shock if dosed aggressively. 19, 20 Angiotensin-converting enzyme inhibitors (ACE-I) also reduce mortality when administered early after ACS. 21, 22 There is also evidence that statins administered early after ACS reduce the risk of death or recurrent ischemic events. 23 β-Blockers, ACE-I, and statins are considered highpriority medications early after ACS.
Acute Stroke
After a transient ischemic attack or ischemic stroke, aspirin reduces the 12-week risk of stroke recurrence (pooled hazard ratio, 0.47; 95% CI: 0.37-0.61) 24 ; however, neuroimaging to exclude intracranial hemorrhage is not widely available in low-resource settings. In a decision analysis, Berkowitz et al 25 stroke of undetermined pathogenesis, aspirin is effective under a range of different settings, suggesting that even if urgent neuroimaging is unavailable, the use of aspirin for stroke is warranted at a population level. This analysis was based on a meta-analysis of 2 large placebo-controlled aspirin stroke trials in which 773 (2% of ≈40 000 presenting with stroke) participants with intracerebral hemorrhage were (inadvertently) administered aspirin/placebo. This study found that aspirin use even in acute intracranial hemorrhage reduces in-hospital mortality and in-hospital second stroke risk-a counterintuitive finding that requires confirmation. Intravenous thrombolysis for ischemic stroke does not reduce mortality (hazard ratio for 90-day mortality among alteplase recipients, 1.11; 95% CI: 0.99-1.25). However, it improves functional outcomes if administered within 4.5 hours of symptom onset. 26 Compared with alteplase, the use of modern intra-arterial thrombectomy devices improves functional outcome after ischemic anterior circulation stroke (odds ratio for a 1-point improvement on the modified Rankin disability scale of 2.35; 95% CI: 1.85-2.98, where, for instance, a 1-point improvement represents the difference between being unable to walk unassisted to able to walk independently), 27 with a trend toward reduced mortality (odds ratio, 0.77; 95% CI: 0.54-1.10). 27 Considering the disability caused by stroke, acute revascularization is high-priority in HIC. In LMIC, the implementation of acute stroke revascularization systems is challenging because of the substantial infrastructure costs and the need for early neuroimaging. Context-specific feasibility and cost-effectiveness research are needed to inform the role of revascularization programs for acute stroke in these settings.
Organized Acute Care Units
Organized coronary care units and stroke units integrate care provided by different disciplines facilitate use of systematic protocols and the delivery of high-quality care at little added cost. Older observational data suggested that coronary care units were associated with improved short-term mortality compared with care on internal medicine wards. 28 Contemporary data on the value of coronary care units are scarce, and older randomized trials of coronary care units were too small to detect plausible benefits.
There is now strong evidence to support the value of stroke units. A meta-analysis of randomized trials of comprehensive stroke units suggests that they reduce death and dependency, improve functional outcomes, and reduce length of hospital stay. 29 Important characteristics of comprehensive stroke units include early (within 24 hours) mobilization, multidisciplinary approach, and prompt initiation of appropriate medications, such as aspirin for ischemic strokes or antibiotics for pneumonia or other infections.
Ambulatory CVD Care Medical Strategies

Vascular Disease
There is clear evidence that aspirin, statins, and pharmacological treatment of hypertension, β-blockers, and ACE-I/angiotensin receptor blockers (ARBs) improve clinical outcomes in individuals with stable CVD. 30, 31 Inadequate uptake of these drugs likely contributes to a substantial number of preventable cases of CVD complications. For example, it has been estimated that globally, 62% of cerebrovascular and 49% ischemic heart disease might be attributable to suboptimal blood pressure (BP) control. 32 Although these estimates are difficult to corroborate, they highlight the importance of adequate risk factor treatment globally. Because most of these drugs are off patent, their costs are relatively low in HIC. Khatib et al 2 documented that in LMIC, aspirin and β-blockers were widely available and affordable but that ACE-I/ARBs and statins were less widely available and relatively unaffordable in LMIC. Because of their efficacy, aspirin, bisoprolol, enalapril, and simvastatin are included in the World Health Organization Essential Medicines 2015 list. Despite these recommendations, the use of these classes of drugs is suboptimal. The PURE study (Prospective Urban Rural Epidemiology)-a large, prospective cohort study of middle-aged adults from HIC, MIC, and LICfound that of 151 966 community-dwelling adults, 7519 (4.9%) had self-reported coronary disease or stroke. Among individuals with coronary heart disease from 3 HIC, 62% took antiplatelet agents, 40% took β-blockers, 50% took ACE-I/ARBs, and 67% took statins. 33 In individuals from 4 LIC, the respective rates of use of these medicines were 9%, 10%, 5%, and 3% 33 ( Figure 1 ). Factors associated with suboptimal use of these secondary prevention medications are diverse and vary from country to country (Table 1) , so promotion of their appropriate use requires consideration of the contextual factors in each country, drug access, availability, and cost. 34, 35 The low availability of these medications is a major barrier to their use in many LMIC. In PURE, while all 4 classes of drug were available in 95% of urban and 90% of rural communities in HIC, all 4 were only available in 25% of urban and 3% of rural communities in LIC. 2 Despite all these drugs being generic, affordability is low in LMIC. Most households in LIC in the PURE study were unable to afford all 4 of these medications simultaneously 2 ( Figure 2 ). It is likely that differences in their use are partly responsible for the higher case-fatality rates after ACS or stroke in LMIC compared with HIC. 36 Beyond availability and affordability, differing priorities, knowledge, culture, and beliefs comprise patient-level barriers to medication adherence in chronic disease. [37] [38] [39] Many of these barriers are unique to the contexts in individual countries, suggesting that a context-specific approach to treatment strategies is necessary. 40 
Atrial Fibrillation
Thromboembolism is a major complication of atrial fibrillation (AF). Antithrombotic agents lower the risk of thromboembolism in patients with AF. In nonvalvular AF, aspirin reduces stroke risk by 22% and warfarin reduces stroke risk by 64%. 41 Adding clopidogrel to aspirin reduces the risk of stroke by a further 28% but is associated with a 57% greater risk of bleeding. 42 Warfarin is more effective than dual antiplatelet therapy in reducing stroke risk (31% RR reduction) 43 and is recommended when at least 1 other stroke risk factor is present. In AF caused by valvular heart disease, warfarin is the accepted treatment although there are no randomized trials to support this recommendation. Direct oral anticoagulants (DOACs-rivaroxaban, apixaban, dabigatran, and edoxaban) that inhibit thrombin or activated factor X are superior to warfarin in preventing stroke and arterial thromboembolism in patients with nonvalvular AF. DOACs have a rapid offset of effect, predictable dose-response relationships, and there is no need for coagulation monitoring. There is a substantial (≈50%) reduction in intracerebral hemorrhage with DOACs as compared with vitamin K antagonists. In a meta-analysis of 4 large, randomized trials comparing a DOAC with warfarin in patients with nonvalvular AF, DOACs reduced stroke or systemic embolism (pooled RR, 0.81; 95% CI: 0.73-0.91) and death (pooled RR, 0.90; 95% CI: 0.85-0.95) 44 compared with vitamin K antagonists. In LIC, the ability to use DOACs without coagulation monitoring is appealing because of limited facilities to measure international normalized ratio. There is evidence from several countries (including Chile, 45 Greece, 46 Taiwan, 47 and the United States 48 ) that DOACs are cost effective compared with vitamin K antagonists at accepted health economic thresholds because of their superior clinical outcomes and the absence of coagulation monitoring requirements. When generic formulations of DOACs become available (by ≈2023), their more widespread uptake will likely lead to improved outcomes in patients with AF globally.
The control of ventricular rate in AF is essential to reduce symptoms and prevent the development of tachycardia-induced cardiomyopathy. Because a therapeutic strategy aimed at controlling ventricular rate is noninferior to a strategy of restoring and maintaining sinus rhythm in AF, 49 rate controlling drugs (β-blockers, diltiazem, and verapamil) are high priority for the management of AF.
Heart Failure
The treatment of the underlying cause of heart failure (HF; eg, correction of valvular heart disease or revascularization for coronary artery disease) is the cornerstone of HF management. There are also several general therapeutic strategies that are beneficial in HF regardless of the underlying pathogenesis. Furosemide and other loop diuretics are foundations for the treatment of pulmonary or peripheral edema in HF. ACE-I/ARBs and β-blockers, both of which interfere with maladaptive neurohormonal responses to HF, reduce morbidity and mortality in patients with HF with reduced ejection fraction. One network meta-analysis of randomized trials estimated the odds ratio (credible interval) for death with ACE-I use is 0.80 (0.71-0.89) and with ARB use is 0.74 (0.62-0.88) 50 while another network meta-analysis of randomized trials estimated the odds ratio (credible interval) for death with β-blocker use is 0.71 (0.64-0.80). 51 Spironolactone that inhibits aldosterone's effects improves mortality in HF with reduced 
Improved knowledge dissemination
Physician performance incentives and quality assessment ejection fraction when used in addition to an ACE-I. 52 Together, ACE-I, β-blockers, spironolactone, and furosemide should be considered high-priority for HF treatment in all settings. Digoxin reduces HF hospitalization and symptoms in patients with HF with reduced ejection fraction and has a neutral effect on mortality. 53 Given its low cost, digoxin is a desirable medication for the treatment of HF, especially in patients with low BP, because it does not affect BP. Two recent, large HF registries, INTER-CHF 54 (An International Registry to Study Current Causes, Treatment, Barriers to Care and Outcomes of Heart Failure in Africa, Asia and South America) and QUALIFY (Quality of Adherence to Guidelines Recommendations for Life-Saving Treatment in Heart Failure: an International Survey), 55 show that these HF medications are widely used in many regions of the world, except sub-Saharan Africa, where financial limitations and low education may prevent their uptake. 54 Recent data indicate that the combination of sacubitril and valsartan is more effective than ACE-I alone in HF with reduced ejection fraction, 56 but at present, it is relatively expensive, so its use is limited even in HICs.
Implantable cardioverter-defibrillators reduce mortality after a nonfatal cardiac arrest from ventricular arrhythmia (secondary prevention) and in those with left ventricular ejection fraction <35%. However, they do not improve quality-of-life and may in fact worsen it because of potential device infection and inappropriate shocks. For this reason, and because of their high costs, although implantable cardioverter-defibrillators are desirable to prevent sudden cardiac death, they are not considered high priority. Cardiac resynchronization by biventricular pacing reduces morbidity and mortality in patients with HF, left ventricular ejection fraction <35%, and a widened QRS complex, however given the limited number of individuals eligible for this therapy, as well as its cost, it should be considered desirable but not a high priority.
Cardiac transplantation can substantially improve survival in highly selected individuals with end-stage HF, but the enormous costs of maintaining a transplant program, including the provision of left ventricular assist devices as a bridge-totransplant, and the management of transplant complications, preclude its widespread use, especially in LMIC.
Surgical Strategies
Arterial Revascularization
Coronary artery revascularization by bypass surgery (coronary artery bypass grafting) is beneficial in those with left main, triple-vessel or double-vessel coronary artery disease that includes the proximal left anterior descending artery. 57 PCI, however, has not been shown to reduce mortality or morbidity compared with medical therapy in those with chronic stable coronary artery disease. 58 There is a relative paucity of cost-effectiveness analysis comparing coronary artery bypass grafting, PCI, and medical therapy for patients with coronary disease. 59 Existing analyses suggest borderline cost effectiveness for coronary artery bypass grafting and PCI in HIC; however, these analyses may be limited in their short time horizon; much of the improvement in quality-adjusted life associated after coronary artery bypass grafting may be explained by its durability. Further research is needed to understand the long-term benefits and costs of arterial revascularization in stable coronary disease.
Carotid endarterectomy results in a 16% absolute reduction in the 5-year risk of ipsilateral ischemic stroke in those with recently symptomatic cerebrovascular disease (transient ischemic attack or nondisabling stroke) and 70% to 99% carotid stenosis, 60 and it is recommended by many guidelines. 61 There are limited cost-effectiveness data on carotid endarterectomy. A UK analysis found that for men <75 years of age, the incremental costeffectiveness ratio of £3254 for carotid endarterectomy is 74% to 84% likely to be cost effective at conventional cost-effectiveness thresholds but is unlikely to be cost effective in those ≥75 years. 62 Carotid endarterectomy is, therefore, a high-priority intervention. Its role in asymptomatic carotid disease is less clear, however. Carotid angioplasty±stenting is a reasonable alternative to carotid endarterectomy in those with symptomatic carotid disease in patients with high risk for carotid endarterectomy.
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Rheumatic Fever, Rheumatic Heart Disease, and Other Valvular Heart Disease Reduction in poverty and overcrowding is key to the primordial prevention of acute rheumatic fever (ARF). The prompt treatment of acute pharyngitis with penicillin (or other antibiotics) to treat group A streptococcus is key for primary prevention of ARF. After an initial attack of ARF, secondary prevention of recurrent attacks is crucial to prevent the development of worsening rheumatic heart disease, including chronic valvular heart disease. Continuous antibiotic prophylaxis, using benzathine penicillin given every 3 weeks, is effective in preventing recurrences of ARF and is recommended for at least 10 years after the initial episode of ARF or until adulthood. 63 Although oral β-lactam antibiotics have not been evaluated in randomized Figure 2 . Proportion of households in the PURE study (Prospective Urban Rural Epidemiology) that may be unable to afford all of aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, β-blocker, and statin (using a 20% of household income threshold), stratified by country income and household wealth. HIC indicates highincome countries; LIC, low-income countries; LMIC, middle-and low-income countries; and UMIC, upper middleincome countries. Reprinted from Khatib et al 2 with permission of the publisher. Copyright ©2016, Elsevier. September 1, 2017 trials, they are also likely to be effective because of universal organism sensitivity in vitro. Comprehensive programs in Cuba, Costa Rica, and Tunisia have virtually eliminated ARF through a combined strategy of education of the public and health practitioners, prompt treatment of pharyngitis with penicillin, secondary prophylaxis, and management of cases with rheumatic heart disease. The enormous decline in rheumatic heart disease in HIC and in selected MIC suggests that these measures are effective. The limited studies from Cuba and Africa indicate that comprehensive programs for prevention of ARF and rheumatic heart disease control are cost effective. 64, 65 Surgical aortic valve replacement for aortic stenosis is a highpriority intervention for severe, symptomatic aortic stenosis or incompetence and for severe asymptomatic aortic valve disease in the presence of impaired left ventricular systolic function. Transcatheter aortic valve implantation (TAVI) represents an important therapeutic advance for individuals with severe, symptomatic aortic stenosis whose surgical risk is prohibitively high. In these patients, TAVI produces a 45% reduction in mortality compared with medical therapy. 66 In addition, TAVI confers a similar risk of death or stroke as aortic valve surgery in individuals with severe, symptomatic aortic stenosis and intermediate surgical risk. 67 Currently, the incremental cost-effectiveness ratio for TAVI in those ineligible for surgical aortic valve replacement ranges from US$27 000 to $65 000 per quality-adjusted life-year gained, which marginally meets accepted willingness-to-pay thresholds in HIC. 68 These specific willingness-to-pay thresholds are not applicable in resource-limited settings, so TAVI is regarded as a desirable technique rather than a high-priority one.
Mitral valve surgery or (in the absence of severe valve calcification) balloon valvuloplasty is recommended for symptomatic, chronic, mitral stenosis. 69, 70 Surgery should be considered for chronic, severe, primary mitral regurgitation with even mild left ventricular dilation in experienced centers. However, some regions with large burdens of valve disease (eg, Sub-Saharan Africa) have inadequate number of centers for invasive or surgical management.
Symptomatic Bradyarrhythmia
Diagnosis of the cause of bradyarrhythmia requires electrocardiography. Although traditional electrocardiography machines may be expensive, new, portable, hand-held, single-lead electrocardiography may facilitate the diagnosis of bradyarrhythmias, especially in rural settings in LIC. Without permanent pacing, the average survival in individuals with symptomatic complete atrioventricular block is estimated at 2.5 years. 71 Permanent pacemakers significantly reduce morbidity and mortality in those with symptomatic high-grade atrioventricular block. One cost-effectiveness analysis estimated that a pacemaker's cost per life-year saved in 2007 was US$773, which represents one of the most cost effective interventions available.
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Prevention Lifestyle Factors
The importance of policy approaches to healthy diet, physical activity, avoidance of tobacco, and alcohol has been reviewed in Part 1 of this series. Policy-based strategies to positively influence behavior are likely to be more impactful than individual-level interventions. With respect to smoking, several pharmacological approaches to assisting smokers to quit have been studied. Although nicotine replacement therapy, bupropion, varenicline, or cytisine might increase abstinence rates by 40% to 70%, [72] [73] [74] these data are limited by potential publication biases and by short follow-up durations.
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Treatment of Hypertension
BP reduction in those with stage 1 (systolic BP, 140-159 mm Hg or diastolic BP, 90-99 mm Hg) or worse hypertension is effective in preventing stroke, coronary heart disease, and HF. 76 A reduction in systolic BP by 10 mm Hg would be expected to reduce stroke risk by 41% (33%-48%) and coronary heart disease risk by 22% (17%-27%) . 77 This benefit is seen irrespective of other risk factors. β-Blockers, ACE-I, ARBs, calcium channel blockers, and diuretics are effective antihypertensive agents, and all have been shown to reduce CVD or mortality. Some of these drugs (β-blockers and ACE-I) are also considered high priority for the treatment of stable vascular disease. The optimal target for achieved BP remains disputed. BP-lowering trials have included heterogeneous populations with different baseline CVD risk and had different approaches to BP measurement and antihypertensive drug titration. 78, 79 At present, there is high-level evidence to support BP-lowering medication for all individuals with systolic BP ≥160 mm Hg or ≥140 mm Hg in those with intermediate risk. 80 Most participants with hypertension require ≥2 drugs to achieve adequate BP control. Starting with a single agent may lead to clinical inertia (because physicians rarely add a second drug and patients usually prefer to avoid additional visits). Increasing evidence suggests that starting treatments with ≥2 drugs is the most efficient and effective strategy to lower elevated BP. 81 Two trials demonstrate that using statins in addition to BP lowering reduces the risk of CVD further, and the 2 together can lead to a 40% to 50% reduction in the risk of CVD events in individuals with hypertension.
82,83
Cholesterol Lowering
The use of statins, which lower cholesterol, and especially lowdensity lipoprotein (LDL) cholesterol, is highly efficacious in preventing ACS, stroke, and cardiac death. The value of statins in those at high risk for adverse CVD events, such as those with known coronary disease, is clear. Previous guidelines recommended using statins to target-specific cholesterol and LDL concentrations; however, recent guidelines emphasize CVD risk to guide statin use and downplay the importance of treating cholesterol to a target value. 84 There does not seem to be a cholesterol threshold at which there is no benefit to the use of statins. 85 Recent evidence with both statins and with the newer PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors indicates that even with initial LDL levels of 1.8 mmol/L, lowering LDL further reduces CVD risk. 85, 86 The recent HOPE-3 study (Heart Outcomes Prevention Evaluation-3) extended on these guidelines by demonstrating that intermediaterisk individuals (10% CVD risk at 10 years), without known CVD, will benefit from statin therapy irrespective of their LDL level. 78 The use of rosuvastatin 10 mg daily in these individuals was associated with a hazard ratio (95% CI) for the composite of cardiovascular death, ACS, or stroke of 0.76 (0.64-0.91).
Antithrombotic Therapy
Aspirin reduces the RR of ACS or stroke by ≈10% in those who have not previously experienced a CVD event and by ≈20% in those who have known CVD. 87 However, it also increases bleeding. High-intensity anticoagulation using vitamin K antagonists is also efficacious in reducing CVD recurrence. In those with known coronary disease, anticoagulation to an international normalized ratio >2.8 reduces CVD death, ACS, or stroke more than aspirin (odds reduction ≈40%). However, it also causes a 4.5-fold increase in major bleeding. 88 This excess of major bleeding prohibited the widespread use of vitamin K antagonists solely to prevent CVD recurrence. The lower lifethreatening bleeding rates observed with DOACs compared with vitamin K antagonists have led to clinical trials evaluating the role of DOACs for the prevention of recurrent CVD. In a randomized trial comparing low doses of rivaroxaban with placebo in patients with a recent ACS (>90% of whom were taking dual antiplatelet therapy), rivaroxaban 2.5 mg twice daily significantly reduced CVD and all-cause mortality. 89 The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) in individuals with stable coronary or peripheral arterial disease, comparing aspirin with rivaroxaban 5 mg twice daily, or rivaroxaban 2.5 mg twice daily plus aspirin, has recently been stopped early because of the beneficial effects of the combination of rivaroxaban and aspirin.
Fixed-Dose Combination Drug Therapy (Polypill)
The polypill that usually contains a combination of antihypertensive medications, aspirin, and a statin has been shown to enhance drug adherence and to result in improved BP and cholesterol concentrations, compared with usual care. 90 The polypill has been shown to have the potential to reduce the population incidence of CVD in a cost-effective manner. 91 Given that these drugs have been separately shown to reduce CVD risk by ≈20% to 25% each, and their effects are independent of each other, a polypill can theoretically reduce CVD risk by >70% to 80%. Even if the results are more modest (eg, a 50% RR reduction), this is clinically worthwhile especially in secondary prevention. By contrast, there is a need for data on clinical outcomes from trials with a polypill in high-risk primary prevention. Formal evaluation of the polypill in those without CVD but at high risk is currently underway in the TIPS3 trial (The International Polycap Study-3) whose results should be available ≈2020. Commercial interest in polypill production is limited because its components are off patent; however, fixed-dose combination drug therapy may represent an attractive health investment for governments to enhance risk factor reduction in intermediate-or high-risk populations.
Diabetes Mellitus
Diabetes mellitus increases the risk of CVD. Glycemic control is likely to be important in reducing the risk of ACS. A meta-analysis of 5 trials comparing intensive with usual glycemic control found that the intensive strategy led to a 0.9% absolute reduction in hemoglobin A1c (from baseline hemoglobin A1c levels ranging from 7.1% to 9.4%) and a significant reduction in nonfatal ACS (pooled odds ratio, 0.83; 95% CI: 0.75-0.93) although a reduction in mortality was not observed (pooled odds ratio, 1.02; 95% CI: 0. 87-1.19) . 92 An older meta-analysis also found that more intensive blood glucose lowering reduces major CVD events (albeit with a more modest pooled hazard ratio of 0.91; 95% CI: 0.84-0.99) without influencing mortality (pooled hazard ratio, 1.04; 95% CI: 0.90-1.20). 93 The blood glucose-lowering drugs studied in these trials were predominantly sulphonylureas, metformin, and insulin. When the beneficial effects of glycemic control on ACS are combined with its proven role in reducing the risk of microvascular diabetic complications, we consider the provision of glucose-lowering drug therapies for diabetes mellitus to be high-priority.
Also, the CVD prevention strategies described above (ie, BP and cholesterol lowering) are highly efficacious in patients with diabetes mellitus. In a randomized trial, a multifactorial intervention (dietary, exercise, smoking cessation, ACE-I/ ARB irrespective of BP, aspirin, treatment of hyperglycemia, hypertension, and hyperlipidemia) reduced CVD rates by 53% in patients with diabetes mellitus and microalbuminuria. 94 Importantly, obesity, physical inactivity, and poor diet quality are all causally related to diabetes mellitus and CVD, so enhancing physical activity and improved diet quality will likely reduce the risk of these 2 related diseases. In adults aged ≥55 years with diabetes mellitus and another CVD risk factor, the ACE-I, ramipril, reduced the risk of ACS, stroke, or CVD death by 25% compared with placebo after adjustment for its BP-lowering effect. 95 Newer glucose-lowering drugs, including semaglutide, 96 liraglutide, 97 (glucagon-like peptide-1 analogues) and empagliflozin 98 (a sodium-glucose cotransporter-2 inhibitor), have recently been shown to reduce CVD incidence rates. Further research is needed to understand how these newer agents incrementally improve CVD event rates and their cost may limit their uptake, even in high-income settings.
Digital Health Interventions
Modern communication tools may enable novel health promotion strategies. According to the Pew Research Center, 95% of Americans own a mobile phone, and mobile phones are also commonplace even in LIC. Frequent (4 per week), tailored text messages can improve CVD risk factors in adults with known coronary disease for a 6-month period. 99 In contrast, a primary prevention trial among South Asian Canadians that used a combination of biweekly e-mails and weekly text messages did not improve CVD risk factors. 100 Although digital health interventions may hold promise, further research is needed to understand what works in which setting. For example, in some traditional societies, access to mobile phones by women may be restricted by cultural norms.
Socioeconomic Status
Many lifestyle-related determinants of CVD health are closely related to socioeconomic status (SES). SES may also be associated with an individual's knowledge of and capacity to access healthcare. In an individual-level meta-analysis of 1 751 479 adults from HIC followed for a mean 13.3 years, those with low SES had ≈35% higher mortality risk than those with high SES.
CI: 1.21-1.32), suggesting that other factors related to high SES, such as differences in care, account for its mortality benefit. Higher education (which is frequently used as a surrogate for SES, but which only captures some aspects of it) has been associated with better CVD outcomes. 102 There is a consistent relationship between higher education levels and presentation at earlier, rather than later, stages of CVD, suggesting that education facilitates earlier recognition of, and action to address, health problems. 13, 14 Unpublished data from the PURE study suggests that those of low SES do not have a higher risk factor burden (other than higher tobacco use in men), but poorer people have less access to healthcare and receive lifesaving medications and procedures less often compared with wealthier people (although this varies, in some LMIC, such as Iran and the Occupied Palestinian Territories, treatment and control of hypertension are relatively equitable). 103 This suggests that the major reason for the SES gradient is poorer healthcare. In a study comparing randomly selected Aboriginal Canadians and Canadians of European ancestry, household income was lower among Aboriginal Canadians, and both risk factor burden and CVD were higher; however, at any given income level, risk factor and CVD burden were still higher among Aboriginal Canadians. 104 These findings point to the need for measures to address wider social and economic inequalities through tax and benefits systems and the provision of universal health coverage (UHC).
Building Capacity for Cardiovascular Interventions
Advances in managing CVD are of limited value if they cannot be delivered to those in most need. More than 60 years after the first well-tolerated antihypertensive medicines became available, the majority of people with hypertension in all parts of the world do not achieve adequate BP control 105 with large inequalities within many countries. 103 This problem of the large gap between evidence and the use of effective treatments is not unique to CVD. The most obvious parallel is with the massive scale-up of antiretrovirals in response to the acquired immune deficiency syndrome epidemic, where it was soon realized that, once the technical challenges of drug discovery and development have been overcome, any population health benefits would be limited without significant investment in health systems strengthening. 106 This recognition has led to a growing interest in health systems strengthening. 107 Interest has been encouraged by the realization that some countries have achieved good healthcare at low cost. 108 The process of health systems strengthening is informed by the identification of a series of building blocks (Figure 3) , all of which must be in place and functioning for those in need to obtain effective and affordable care. 109 The configuration of health services can have a major impact on the ability of individuals to access care. Access is a complex construct, with spatial, temporal, and cultural elements. 110 Rates of treatment are often higher among individuals who live closest to health facilities, 111 with at least 1 study finding a positive association with hypertension control. 112 Even nearby health facilities may, in effect, be inaccessible, if their opening hours do not coincide with when people can attend. 113 Finally, even if the facilities exist and are open, if they are unwelcoming, with inadequate or misleading signage, unfriendly staff, or perceived discriminatory behavior, they are less likely to be used. 114 The health workforce plays a critical role in the diagnosis and management of CVD. It is important to consider both the quantity and quality of the health workers. Although there is some evidence that hypertension control is better with more senior physicians, 115 in many parts of the world, there are severe shortages of any kind of health workers. This has led policymakers to explore using nonphysician health workers, who have received training in a narrow range of conditions and the use of a limited number of treatments. 116 There is growing evidence that nonphysician health workers can be effective in bringing care to under-resourced areas. 117 Through improved, cost-effective CVD screening, lifestyle counseling, and medical management, facilitated by task-sharing with nonphysician health workers, many barriers to evidence-based practice might be overcome.
The third building block is information. At the population level, policies can be guided by epidemiological data, identifying the extent to which need is translated into demand and, ultimately, use. Information also contributes to effective care by enabling health workers to know what works and what does not. Although difficult to quantify, a substantial part of the decline in CVD events for recent decades is likely to have been a result of the application of evidence from research. Information also includes the growing volume of health services research, identifying not only what works but also in what circumstances and for whom. 118 The fourth building block comprises key medicines and technology. Although, as noted above, there are efficacious medicines for CVD, a major challenge is to ensure that these medicines reach those in need. Yet, this is not the case in many parts of the world, with medicines being either unavailable or unaffordable. 2 The supply chain from manufacturer to local pharmacy is long and complex, with considerable scope for blockages, delays, and profiteering. These problems are exacerbated by the increasing presence of organized crime, in particular, through the production of counterfeit medicines 119 and the diversion of publicly funded medicines to the private sector. 120 However, many of the problems are simply because of weak managerial systems, resulting in stock outs and wastage.
The fifth building block is the financing of the health system. Many governments of the world have recognized the importance of UHC, including it in the Sustainable Development Goals. 121 The coverage of healthcare costs from pooled funds enables efficiencies that cannot be accomplished in a healthcare system where medical services are paid for on a user-pay out-of-pocket basis. For example, compared with the individual, the insurer can procure medicines at lower cost as a bulk purchase; more easily avoid the purchase of counterfeit medications; and leverage the provision of high-quality, evidence-based treatments by healthcare providers. Paying for healthcare is, however, intrinsically political because it involves redistributing resources from rich to poor, from healthy to ill, and from those of working age to those at the extremes of life. As with all approaches to redistribution of resources, the choices that are made reflect prevailing values in a society, as well as the (often) uneven distribution of political power. This is exemplified by the recent debate in the United States about the Affordable Care Act, in which proposals that were politically and practically unworkable were promoted not because they would improve access to care but instead because they would release funds for other purposes. 122 In 2012, at least 89% of the population in each country in the Organization for Economic Co-operation and Development were insured by the government, except the United States, where 33% were covered by government health insurance. There was a continuous positive relationship between the percentage of gross domestic product spent on health and health outcomes (as measured by female life expectancy, Figure 4) ; however, the United States is an outlier, with substantially higher healthcare expenditure, which does not seem to translate into improved health outcomes. These observations suggest that although the prioritization of healthcare as a budget item translates into improved health outcomes, an UHC health system model is more efficient than a more free-market health system. Among the predominantly MIC of Latin America, the 1980s witnessed policies to address social inequalities and to provide UHC. These strategies were followed by progressive improvement in key health indicators, such as survival ( Figure 5 ), which provides further evidence to suggest that UHC improves population health. 123 Although there are several ways of raising money to pay for healthcare, there is consistent evidence that progressive taxation is most effective in creating health systems that maximize coverage. 124 The final building block relates to leadership and governance. These are linked to the concept of stewardship, whereby it is recognized that healthcare cannot simply be left to the action of market forces 125 because healthcare exemplifies the problems of market failure, including asymmetry of information and externalities. 126 There is a need for systems that can anticipate emerging health needs and identify opportunities for new forms of prevention and treatment. In this context, the growth of multimorbidity is a particular challenge. 127 As populations age, increasing numbers of people have multiple conditions, each requiring input from a range of specialists. The design of a health system that can ensure a seamless journey along what are often complex pathways of care can be extremely challenging, but there is accumulating experience with strategies that integrate, for example, services for human immunodeficiency virus/acquired immune deficiency syndrome and noncommunicable diseases. 128 However, implementation of innovative solutions requires a clear vision, leadership, and mechanisms to implement change.
Last, although the implementation of evidence-based practices is crucial to the global prevention and treatment of CVD, the deimplementation of ineffective or harmful interventions is also important when evidence against their value emerges. The barriers preventing the implementation of evidence-based practices, including lack of knowledge at the health-provider level, clinical inertia, and financial incentives, also limit the deimplementation of ineffective interventions. 129 Further development of effective strategies for both the implementation of evidence-based interventions and the deimplementation of ineffective or harmful therapies is required.
In summary, health systems have a large role in reducing the burden of CVD because they are essential to translate evidence from research into practice. However, if they are to achieve their potential, it is essential that they draw on the best available evidence within an effective system of governance.
Priority Setting
Although specific CVD treatment and preventive strategies are considered high-priority in this article, economic constraints must be acknowledged, and the opportunity cost of these high-priority strategies evaluated within a broader context. It is beyond the scope of this article to prioritize CVD therapies in relation to non-CVD therapies or other budgetary demands. For instance, expanding coverage for coronary bypass surgery may not be ethically acceptable if it occurs at the expense of the treatment of potentially fatal but reversible childhood diseases, such as common infections.
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Cost Effectiveness
Given the limitations in the financial resources made available for healthcare, the selection of which treatment and prevention strategies are implemented may be informed by cost-effectiveness studies to assess the incremental cost-effectiveness ratio and the cost-effectiveness threshold (CET). The incremental cost-effectiveness ratio is an estimate of the cost per quality-adjusted life-year gained by a new intervention as compared with an alternative or control. The incremental cost-effectiveness ratio can be compared with the CET, which is an estimate of the effect of withdrawing an amount of money from the healthcare budget (ie, the opportunity cost of a new intervention). If the incremental cost-effectiveness ratio is less than the CET for a given intervention, then the economic model suggests that the intervention will increase the population's overall health. Several CETs established in HIC are widely cited (eg, US$50 000 in the United States) although these are, inevitably, largely a matter of judgment and several are now old. 131 Another challenge in the use of cost-effectiveness studies to inform policy is that their findings may not be generalizable to other countries because of differences in the inputs required and their costs, both of the intervention in question and alternatives. Even within a country, cost-effectiveness estimates can vary widely, depending on the assumptions made in the model. 132, 133 Furthermore, the value placed on life-years gained and the quality weighting associated with living with illness will also likely influence cost-effectiveness estimates among different countries. In LIC, there is a paucity of CET data 134 and even of cost data. 135 Further research, especially in low-resource settings, would help prioritize health spending, although in practice, CETs are more likely determined by the available budget than by willingness-to-pay research.
Future Challenges
Globally, there have been substantial improvements in life expectancy 136 because of better prevention (especially tobacco control) and the increasing (albeit, incomplete) use of interventions that reduce mortality and morbidity. Consequently, populations are ageing with a high prevalence of multimorbidity. 127 This epidemiological transition is most pronounced in HIC and will likely spread increasingly to LICs as their healthcare systems evolve. To minimize the societal burden of multimorbidity and accompanying disability in an ageing population, increasing emphasis should be placed on the primary and primordial prevention of CVD (Tables 2 and  3 ) because the high-priority elements of CVD treatment are implemented.
In HIC, advances in the identification and management of those with CVD risk factors associated with particularly high risk, such as diabetes mellitus, or established CVD have led to significant improvements in their mortality rates. 146 In contrast, in an age-and sex-matched cohort without diabetes mellitus from the same administrative database, there was much less improvement in CVD event rates during the past decade. 146 This observation highlights the need to develop population strategies aimed at the primordial prevention of CVD, in addition to primary prevention (ie, in those with known risk factors) and secondary prevention (ie, in those with established CVD).
Conclusions
The past 4 decades have witnessed substantial increases in our knowledge of how to prevent and treat CVD and its risk factors, and this has translated into marked reductions in CVD mortality rates in HIC especially, such that many countries have reduced premature deaths from CVD by >50%. MIC have also demonstrated improved health outcomes after the implementation of UHC, now included as a target in the Sustainable Development Goals. However, most LIC have not shown reductions in CVD mortality. The implementation of treatment strategies in a cost-effective manner remains a major challenge in LIC, as do treatment affordability, accessibility, and equity. Approaches, such as expanding the use of nonphysician health workers to implement high-priority interventions, are likely to be effective in affordably improving health outcomes. The primordial prevention of the development of CVD risk factors and a better understanding of how to treat CVD effectively in the context of multimorbidity are also important emerging challenges for the global reduction of CVD burden. 
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